Cisapride (prokinetic)

Cisapride is a prokinetic medication that enhances gastrointestinal motility by stimulating serotonin 5-HT4 receptors in the gut wall, making it an essential tool in small mammal medicine where gastrointestinal stasis represents a common and potentially life-threatening condition. This medication increases the coordinated contractions of the stomach and intestines that move food through the digestive tract, helping to restore normal gut function in patients experiencing motility disorders. In exotic veterinary practice, cisapride has become indispensable for managing GI stasis in rabbits, guinea pigs, chinchillas, and other small herbivores where gut hypomotility can rapidly progress to a critical condition.

The history of cisapride in veterinary medicine is intertwined with its complicated status in human medicine. Originally marketed as Propulsid for human use, the medication was withdrawn from the general market in 2000 due to cardiac side effects, specifically QT prolongation leading to potentially fatal arrhythmias. However, the medication remained available through limited access programs and compounding pharmacies, and veterinary use continued because the cardiac risks that prompted withdrawal in humans appear to be less significant in most animal species. Today, cisapride is available exclusively through compounding pharmacies for veterinary use.

Cisapride works throughout the gastrointestinal tract, stimulating motility from the esophagus through the colon. The medication enhances the release of acetylcholine at the neuromuscular junction of gut smooth muscle, resulting in stronger and more coordinated peristaltic contractions. This broad spectrum of action makes cisapride effective for various motility disorders including gastric stasis, small intestinal ileus, and colonic hypomotility. The medication does not have significant effects on gastric acid secretion, distinguishing it from some other GI medications.

The availability of cisapride through compounding pharmacies has been crucial for exotic veterinary medicine, where GI stasis is among the most common emergencies encountered. Compounding allows preparation of appropriate concentrations and flavoring for small mammal patients, as no commercial veterinary products exist. While compounded products may have some variability compared to manufactured pharmaceuticals, quality compounding pharmacies can provide reliable formulations that have proven effective in clinical practice.

Cisapride is primarily indicated for the treatment of gastrointestinal stasis and hypomotility disorders in small mammals, conditions that can rapidly become life-threatening in hindgut fermenters that depend on continuous gut function for survival. GI stasis, characterized by reduced or absent gut motility, allows gas and toxins to accumulate, causes pain and anorexia, and can progress to hepatic lipidosis and death if not promptly addressed. Cisapride helps restore the coordinated peristaltic contractions necessary for normal digestive function, making it a cornerstone of GI stasis treatment protocols.

In rabbits, cisapride is extensively used for GI stasis, one of the most common conditions seen in rabbit medicine. Rabbits are obligate hindgut fermenters that cannot vomit, making functional gut motility absolutely essential for their survival. GI stasis in rabbits can be triggered by dietary issues, stress, pain, dental disease, and numerous other factors. Cisapride helps restart gut motility while other treatments address the underlying cause and provide supportive care. The medication is often continued for days to weeks until normal gut function is firmly reestablished.

Guinea pigs and chinchillas benefit from cisapride therapy when GI hypomotility develops, though the presentation and management may differ somewhat from rabbits. These species are also hindgut fermenters dependent on continuous cecal fermentation, making gut stasis similarly dangerous. Chinchillas in particular can develop GI stasis related to dental disease, environmental stress, or dietary changes. Cisapride helps restore motility while comprehensive treatment addresses all contributing factors.

Ferrets may receive cisapride for GI motility disorders, though their carnivorous digestive system differs significantly from herbivorous small mammals. Gastric stasis in ferrets can occur with hairballs, foreign body ingestion, or systemic illness. Cisapride can help promote gastric emptying and intestinal motility in affected ferrets. However, ferrets may be more susceptible to the cardiac effects of cisapride than some other species, requiring careful consideration of risks and benefits.

Small rodents including hamsters, gerbils, rats, and mice may receive cisapride for motility disorders, though their small size presents dosing challenges. Post-surgical ileus is a potential application in these species, as abdominal surgery can temporarily disrupt normal gut motility. The medication may also have applications in managing chronic constipation or megacolon conditions in rodent species. Careful dosing using compounded preparations appropriate for very small patients is essential.

Dosing of cisapride in small mammals must be determined by a veterinarian experienced with the target species, as significant variations exist in appropriate dosing across different species and clinical situations. The medication is used extra-label in all small mammal species, requiring professional judgment to balance efficacy against potential risks. The veterinarian will calculate an appropriate dose based on the patient's body weight, the severity of the motility disorder, and the specific clinical context.

Oral administration is the standard route for cisapride therapy in small mammals. The medication is typically given before meals when possible, as this timing optimizes the prokinetic effect to enhance gastric emptying and intestinal transit of ingested food. However, in patients with complete anorexia, timing relative to meals may be less relevant, and the focus shifts to stimulating baseline gut motility to prevent further deterioration.

Cisapride is exclusively available through compounding pharmacies, which can prepare oral suspensions or other formulations suitable for small mammal patients. Liquid suspensions are particularly useful for accurate dosing in very small patients and for patients that have difficulty accepting solid medication forms. Compounding pharmacies can also add flavoring agents to improve palatability, though individual patient preferences vary. The veterinarian will specify the appropriate concentration to facilitate accurate dosing for the specific patient.

The frequency of cisapride administration typically ranges from two to four times daily, depending on the species and clinical situation. More frequent dosing may be necessary during acute GI stasis when aggressive prokinetic therapy is needed, while less frequent maintenance dosing may be appropriate as gut function improves. The veterinarian will establish an appropriate dosing schedule and adjust frequency based on the patient's response to treatment.

Duration of cisapride therapy varies considerably depending on the underlying cause of GI hypomotility and the patient's response to treatment. Acute GI stasis may respond to relatively short-term therapy of several days to a week, while chronic motility disorders or situations where the underlying cause cannot be fully resolved may require longer-term or ongoing cisapride administration. The veterinarian will determine appropriate treatment duration based on clinical progress.

Owners administering cisapride at home should receive thorough instruction in proper technique for their specific species and patient. Accurate measurement of the prescribed dose is essential, particularly with compounded liquid preparations where dosing volumes may be small. Maintaining consistent timing of doses helps optimize the prokinetic effect and provides the most benefit for the patient's gut motility.

Cisapride is generally well-tolerated in small mammal patients when used at appropriate doses, though side effects can occur and require monitoring. The most significant concern with cisapride relates to cardiac effects, specifically the potential for QT prolongation that led to the medication's withdrawal from the human market. While veterinary patients appear less susceptible to these cardiac effects than humans, the potential exists and should be considered, particularly in patients with pre-existing cardiac conditions or those receiving other medications that affect cardiac conduction.

Gastrointestinal effects represent the most commonly observed side effects of cisapride therapy in small mammals. These effects are generally extensions of the medication's therapeutic action and may include increased frequency of defecation, softer stools, or mild diarrhea. In patients with severe GI stasis, increased fecal output is typically a welcome sign of treatment response rather than an adverse effect. However, excessive diarrhea or signs of abdominal discomfort should be reported to the veterinarian.

In guinea pigs, chinchillas, hamsters, gerbils, and rabbits, monitoring gastrointestinal function during cisapride therapy is particularly important due to these species' dependence on hindgut fermentation. While cisapride is specifically intended to improve GI function, overstimulation of gut motility could theoretically disrupt normal fermentation processes. Signs to monitor include changes in fecal pellet size, consistency, and quantity, as well as appetite and overall demeanor. Any significant changes should be reported to the veterinarian.

Abdominal cramping or discomfort may occasionally occur with cisapride use, manifesting in small mammals as hunched posture, reduced activity, teeth grinding, or reluctance to eat. These signs can be difficult to distinguish from symptoms of the underlying GI condition being treated, requiring veterinary assessment to determine whether symptoms represent disease progression or medication side effects. Dose adjustment may be necessary if cramping is attributed to cisapride.

Neurological effects including restlessness, tremors, or seizures have been rarely reported with cisapride use in animals. These effects are uncommon at therapeutic doses but may occur with overdose or in particularly sensitive individuals. Any neurological abnormalities during cisapride therapy warrant immediate veterinary attention and discontinuation of the medication pending evaluation.

Cisapride has several important contraindications that must be considered before initiating therapy in small mammal patients. Gastrointestinal obstruction represents an absolute contraindication to cisapride use, as stimulating gut motility against a mechanical blockage can cause intestinal rupture with potentially fatal consequences. Before starting cisapride therapy, the veterinarian must be reasonably confident that no obstructive process is present. Diagnostic imaging may be necessary to rule out obstruction in patients with GI stasis of unclear etiology.

Gastrointestinal perforation or hemorrhage contraindicate cisapride use, as stimulating motility in a compromised intestinal tract could worsen these life-threatening conditions. Patients with known or suspected GI perforation require surgical intervention rather than prokinetic therapy. Similarly, active GI bleeding should be controlled before considering motility-enhancing medications that could potentially displace clots or worsen hemorrhage.

Pre-existing cardiac conditions, particularly those involving QT prolongation or arrhythmias, represent relative contraindications to cisapride use. While cardiac effects are less common in veterinary patients than in humans, patients with known heart disease should be carefully evaluated before cisapride therapy. Alternative prokinetic agents such as metoclopramide may be preferable in patients with significant cardiac concerns, though metoclopramide has its own limitations and side effect profile.

Known hypersensitivity to cisapride would contraindicate its use, though true allergic reactions to the medication are rare. Patients that have previously experienced adverse reactions to cisapride should not receive the medication without careful veterinary assessment. If cisapride is the only appropriate prokinetic option for a patient with previous adverse reactions, close monitoring during therapy would be essential.

Cisapride has several significant drug interactions that require careful consideration in small mammal patients receiving multiple medications. The most important interactions involve medications that affect cardiac conduction or that alter cisapride metabolism, potentially increasing the risk of cardiac adverse effects. Veterinarians must review all concurrent medications before prescribing cisapride and adjust treatment protocols accordingly.

Medications that prolong the QT interval should generally not be combined with cisapride due to additive cardiac effects. This includes certain antiarrhythmics, some antibiotics including erythromycin and other macrolides, and various other medications. In small mammal medicine, macrolide antibiotics might be considered for certain infections, making awareness of this interaction particularly important. If both cisapride and a potentially interacting medication are necessary, cardiac monitoring and careful risk-benefit assessment are warranted.

Inhibitors of cytochrome P450 3A4, the enzyme responsible for cisapride metabolism, can increase cisapride blood levels and potentially increase the risk of adverse effects including cardiac complications. Ketoconazole, itraconazole, and other azole antifungals are significant CYP3A4 inhibitors that should generally not be combined with cisapride. Since azole antifungals are commonly used in small mammal medicine for various fungal infections, this interaction has practical clinical relevance.

Anticholinergic medications may counteract the prokinetic effects of cisapride, potentially reducing its therapeutic benefit. Anticholinergics reduce gut motility, working in opposition to cisapride's mechanism of action. If both types of medication are being used for different therapeutic goals, the net effect on GI motility may be unpredictable. The veterinarian may need to adjust timing or dosing if anticholinergic medications cannot be avoided in a patient requiring prokinetic therapy.

Several important precautions guide the safe use of cisapride in small mammal patients. The cardiac risks that prompted cisapride's withdrawal from the human market, while apparently less significant in most veterinary species, should not be entirely dismissed. Patients with known cardiac disease, electrolyte imbalances, or those receiving other medications that affect cardiac conduction require careful evaluation before cisapride therapy. Baseline cardiac assessment may be warranted in high-risk patients.

Electrolyte imbalances, particularly hypokalemia and hypomagnesemia, can increase the risk of cisapride-induced cardiac effects. Patients with GI stasis often develop electrolyte abnormalities due to reduced food intake and potential fluid losses, making this consideration particularly relevant. Correction of electrolyte imbalances before or concurrent with cisapride therapy may help reduce cardiac risks. Fluid therapy and nutritional support are often provided alongside prokinetic therapy as part of comprehensive GI stasis management.

The importance of ruling out mechanical obstruction before initiating cisapride therapy cannot be overstated. GI stasis and mechanical obstruction can have similar presentations, but treatment approaches differ dramatically. Stimulating gut motility against an obstruction can cause intestinal rupture, a catastrophic complication. When the cause of GI hypomotility is uncertain, diagnostic imaging including radiographs or ultrasound should be performed to evaluate for obstructive processes before starting prokinetic therapy.

Monitoring during cisapride therapy should include assessment of GI function through observation of appetite, fecal output, and abdominal comfort. Response to prokinetic therapy typically includes improved appetite, resumption of normal fecal production, and improved activity level. Lack of improvement or worsening of symptoms despite appropriate therapy should prompt reevaluation of the diagnosis and treatment plan.

Human safety during handling of cisapride is generally not a significant concern, as the medication is not readily absorbed through skin contact. However, standard medication handling precautions should be followed, including handwashing after administration. Pregnant women or individuals with cardiac conditions might choose to have another family member administer the medication, though the risk from handling small amounts of compounded cisapride is minimal.

Proper storage of cisapride preparations is essential for maintaining medication potency, particularly important given that all cisapride products used in small mammals are compounded preparations rather than commercially manufactured pharmaceuticals. Compounded medications may have reduced stability compared to manufactured products, making appropriate storage even more critical. Following the compounding pharmacy's specific storage instructions ensures the medication remains effective throughout the treatment period.

Most compounded cisapride oral suspensions require refrigeration to maintain stability and prevent microbial contamination. The beyond-use date assigned by the compounding pharmacy should be strictly observed, as compounded liquid preparations typically have limited stability periods. Any changes in appearance, consistency, color, or odor of the suspension should prompt disposal and replacement with a fresh supply rather than continued use of potentially degraded medication.

Protection from light may be recommended for some cisapride preparations, as the medication can be sensitive to photodegradation. Storage in the original container provided by the compounding pharmacy, which may be amber or opaque to limit light exposure, helps maintain stability. The medication should be kept in a secure location away from children and non-target animals, as accidental ingestion could cause adverse effects.

Disposal of unused or expired cisapride should follow local guidelines for medication disposal. Many communities offer medication take-back programs or designated disposal sites that accept unused pharmaceuticals. If these options are not available, specific household disposal methods may be recommended, though flushing medications is generally discouraged due to environmental concerns. The compounding pharmacy may be able to provide guidance on appropriate disposal methods for unused cisapride preparations.

Rabbits represent perhaps the most common patient population receiving cisapride in exotic practice, as GI stasis is extremely prevalent in this species and prokinetic therapy is a cornerstone of treatment. Rabbits are obligate hindgut fermenters with a specialized digestive system that requires continuous motility to function properly. GI stasis in rabbits can develop from numerous causes including stress, pain, inappropriate diet, dental disease, and environmental changes. Cisapride helps restore gut motility while comprehensive treatment addresses all contributing factors. Most rabbits respond well to cisapride therapy when used as part of a complete treatment protocol.

Guinea pigs and chinchillas share many similarities with rabbits in their dependence on hindgut fermentation and their susceptibility to GI hypomotility. These species can develop GI stasis from dietary issues, dental problems, stress, or systemic illness. Cisapride therapy in guinea pigs should be accompanied by vitamin C supplementation if dietary intake is reduced, as these animals cannot synthesize their own vitamin C. Chinchillas may be particularly sensitive to environmental stressors that can trigger GI disturbances, and treatment should address stress reduction alongside prokinetic therapy.

Ferrets can receive cisapride for motility disorders, though their carnivorous digestive system differs significantly from herbivorous small mammals. Gastric stasis in ferrets is commonly associated with hairballs, foreign body ingestion, or systemic illness. Ferrets may be more susceptible to cardiac effects of cisapride than some other species, and careful monitoring is warranted. The carnivorous ferret gut responds differently to prokinetic therapy than the herbivore gut, and treatment expectations should be adjusted accordingly.

Small rodents including hamsters, gerbils, rats, and mice may receive cisapride for various motility disorders, though their small size necessitates careful compounding for accurate dosing. These species can develop GI hypomotility from various causes including post-surgical ileus, stress, and systemic illness. Hedgehogs and sugar gliders may also benefit from prokinetic therapy in appropriate clinical situations, though clinical experience with cisapride in these species is more limited. Each species has unique digestive physiology that may affect response to prokinetic therapy.

Metoclopramide represents the primary alternative prokinetic agent to cisapride in small mammal medicine, working through both dopamine antagonism and serotonin agonism to enhance GI motility. While metoclopramide has the advantage of being commercially available without compounding, it has a different side effect profile including potential for neurological effects such as behavior changes and extrapyramidal signs. Metoclopramide may be preferred in patients with significant cardiac concerns where cisapride's potential cardiac effects are a greater worry, while cisapride may be preferred in patients where neurological effects are a concern.

Simethicone is often used alongside cisapride in the management of GI stasis, particularly in rabbits and other species where gas accumulation contributes to abdominal discomfort and reduced gut motility. Simethicone is an anti-foaming agent that helps break up gas bubbles rather than a prokinetic agent, making it complementary to rather than a substitute for cisapride. The combination addresses both the gas accumulation and the underlying hypomotility that characterizes GI stasis.

Ranitidine, while primarily an H2 receptor antagonist used for gastric acid reduction, also has mild prokinetic properties and is sometimes used in combination with or as an alternative to more potent prokinetic agents. Other supportive medications commonly used alongside cisapride in GI stasis management include pain medications to address the discomfort associated with gut hypomotility, appetite stimulants to encourage food intake, and fluid therapy to maintain hydration and support gut function. The veterinarian will determine the most appropriate combination of medications based on the specific clinical situation and the needs of the individual patient.